1. Diagnosis, disease notification, and management of rapid eye movement (REM) sleep behavior disorder.
- Author
-
Shimohata T, Inoue Y, and Hirata K
- Subjects
- Clonazepam therapeutic use, Diagnosis, Differential, Humans, Neurodegenerative Diseases diagnosis, Neurodegenerative Diseases etiology, Neurodegenerative Diseases metabolism, Neurodegenerative Diseases therapy, REM Sleep Behavior Disorder etiology, REM Sleep Behavior Disorder psychology, Stress, Psychological, Truth Disclosure, alpha-Synuclein metabolism, REM Sleep Behavior Disorder diagnosis, REM Sleep Behavior Disorder therapy
- Abstract
Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment behavior during REM sleep. It has been demonstrated that patients with idiopathic RBD are at a significantly increased risk of developing one of the α-synucleinopathies later in life, and this is called "phenoconversion". Although some physicians argue against disclosing information that could cause patients psychological stress, the patients also have a "right to know" about their own disease. Therefore, determining when and how to disclose this information, in addition to appropriate follow-up, is important. Clonazepam is the first choice of treatment for RBD associated with α-synucleinopathies. Since RBD is one of the premotor symptoms of α-synucleinopathies, and enables its early diagnosis, a combination of RBD and other examinations may contribute to the realization of a disease-modifying therapy. It is hoped that the early establishment of biomarkers could help predict the phenoconversion from RBD to α-synucleinopathies.
- Published
- 2017
- Full Text
- View/download PDF